Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Outlook Therapeutics Inc (OTLKW)

Outlook Therapeutics Inc (OTLKW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter GlobeNewswire - Wed Feb 11, 7:45AM CST

ISELIN, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.5030 (+14.06%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development GlobeNewswire - Tue Jan 6, 7:35AM CST

ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.5030 (+14.06%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD GlobeNewswire - Wed Dec 31, 2025

ISELIN, N.J., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.5030 (+14.06%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Announces New Employment Inducement Grants GlobeNewswire - Fri Dec 26, 2025

ISELIN, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.5030 (+14.06%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 GlobeNewswire - Fri Dec 19, 2025

ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.5030 (+14.06%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference GlobeNewswire - Mon Nov 24, 2025

ISELIN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.5030 (+14.06%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD GlobeNewswire - Thu Nov 13, 2025

Prescription Drug User Fee Act (PDUFA) goal date of December 31, 2025 ISELIN, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused...

OTLK : 0.5030 (+14.06%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 GlobeNewswire - Mon Nov 3, 2025

ISELIN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of...

OTLK : 0.5030 (+14.06%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Provides Update on Type A Meeting with FDA GlobeNewswire - Mon Sep 29, 2025

ISELIN, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.   (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment...

OTLK : 0.5030 (+14.06%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Requests Type A Meeting with FDA GlobeNewswire - Tue Sep 2, 2025

ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment...

OTLK : 0.5030 (+14.06%)
OTLKW : 0.03 (-1.96%)

Barchart Exclusives

This New ETF Bolsters ‘America First’ Tech Stocks in Defiance of 'Sell America' Trade Barchart - 2 minutes ago
As the "sell America" trade has gained popularity, the launch of USMD is doubling down on "America First" tech trades. Here's what to know. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot